about
The Yin and Yang of Toll-like receptors in cancerDelivery of host cell-directed therapeutics for intracellular pathogen clearanceCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study.Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.Dendritic cell-based human immunodeficiency virus vaccine.Trial Watch: Toll-like receptor agonists in oncological indications.In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.Toll-like receptor agonists in cancer therapy.Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cellsLipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.Trial Watch: Peptide-based anticancer vaccines.Tumor immunosurveillance in human cancers.Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFα in monocytes.Toll-like receptor signaling in neural plasticity and disease.Upregulation of TLRs and IL-6 as a marker in human colorectal cancer.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.The TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.Differential macrophage programming in the tumor microenvironment.Development of an Enhanced Phenotypic Screen of Cytotoxic T-Lymphocyte Lytic Granule Exocytosis Suitable for Use with Synthetic Compound and Natural Product Collections.Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells.Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.Insights on the mechanism of action of immunostimulants in relation to their pharmacological potency. The effects of imidazoquinolines on TLR8.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancerChemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancerVaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicityTLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.Toll-like receptors in prostate infection and cancer between bench and bedsideReversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.Combinations of TLR ligands: a promising approach in cancer immunotherapy.Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling.Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.Flt3L dependence helps define an uncharacterized subset of murine cutaneous dendritic cells
P2860
Q26851526-EAA9BA24-0CE3-4921-BA9D-F75BD7CC8E90Q27006858-E37F0A7D-E52B-40E6-801F-68AB43B7A13DQ30358185-CAC1A8C3-9A50-4213-B1B1-A0A91CEB5FCAQ33681786-B6AE3538-DE9E-4E95-AA90-BC88863771E9Q33755300-19C7F070-539D-4792-A160-A49F5610EC2EQ33766970-7D782885-8022-44F1-920D-C19A17FB10F1Q33874652-FEC3057A-C7E6-4F27-9AA4-C2CCE7C4CE63Q33878578-E1111E73-6A8C-43CF-B0B7-7895D7002943Q33901007-E5E45172-5F99-4E6F-9355-0751FC3AFA69Q33918509-DA1CA180-CA6A-4FF1-BF28-76F4833F4D6FQ34140756-A68CAD88-2121-4BAB-BA2E-8AFECE37FF59Q34149109-9BCBCA77-EFD7-4D7A-A441-D40AC69BB47FQ34197336-328A1248-AC33-4185-BEDA-1494F3B9A2A7Q34275796-3D81C510-8216-43B1-8F83-5FAB3C4E8AC3Q34483345-632497D6-B1F9-4C39-A7F2-4BFCD0F35210Q34601529-985AD366-F3AC-4411-9AAA-147A871C6CDCQ34802780-32306908-8EED-47F0-8DE5-38CF1A8ACF5DQ34984865-B4009AC1-9500-4FE7-B9C7-CE5633F83EECQ35016401-D41FD5C9-320E-4D35-BEBB-96E7D9A23FA6Q35018021-664D451D-DD53-4F4A-95E6-E67B785DA197Q35116211-E4A17358-0CCB-4985-B1B6-537383115A0BQ35186756-743D0C98-744A-42B7-B6D2-9BED1F78E103Q35803027-0096A298-D720-4825-B637-5C3A4741EED9Q35980435-F7458B34-F1A1-4FCF-8F84-8F7A7847F86FQ36096165-FEFB533C-8C14-4F0F-B803-AE8B7B54B157Q36215126-5FFB66EE-0029-4930-9C0E-2421BDEFFCFEQ36393002-DBBC1F92-962D-46CB-9486-8CA4F6A2FB1AQ36476394-687D6F64-3AE1-481C-B11D-8D8E2074876DQ36501284-78D318A8-3A6C-4B3C-893A-1DF1715C7F74Q36632306-BD7AFBE6-EF87-4590-BC21-0F43276DDAB1Q36847343-9CB6B24A-02A1-40F2-A4CB-C3C0DB9ED369Q36941127-D2AE606E-8168-4975-94A2-BE9C4BA870EAQ37295411-F23FD2B4-559C-4DED-AA73-3F83194022BCQ37349884-D0AB9B94-B08A-4451-A33F-9A1B1AB023C4Q37383587-857323EC-DCD7-4B8A-9981-66EAF4740C5CQ37463994-01DCBC0E-91EA-481B-9E28-928ACCDD70FDQ37497786-9225F4C7-34A6-4974-9C18-19293984919AQ37522371-BC7F61FD-06FF-4EBC-A2EB-F16C9A27E24EQ37530899-0BFE5C8C-0AB4-462A-B061-55EC55C29FF9Q37715466-06F908CE-3AFD-44F7-A4A5-DFD4A92C1929
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TLR7 and TLR8 as targets in cancer therapy.
@en
TLR7 and TLR8 as targets in cancer therapy.
@nl
type
label
TLR7 and TLR8 as targets in cancer therapy.
@en
TLR7 and TLR8 as targets in cancer therapy.
@nl
prefLabel
TLR7 and TLR8 as targets in cancer therapy.
@en
TLR7 and TLR8 as targets in cancer therapy.
@nl
P2860
P356
P1433
P1476
TLR7 and TLR8 as targets in cancer therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210913
P407
P577
2008-01-01T00:00:00Z